|
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease Clinical research trials and Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease. Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease clinical trial. Human subjects frequently get the finest healthcare available for their Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease  Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
For Condition: Cystic Fibrosis
Status: No longer recruiting
Sponsor(s): Inspire Pharmaceuticals , Cystic Fibrosis Foundation Therapeutics
Synopsis: The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease. Study drug will be administered through a nebulizer (a device that delivers medication as a mist by breathing it in).
Details: The purpose of this study is to: - assess the safety and efficacy of multiple dose levels of INS37217 compared to placebo over 28 days in subjects with mild to moderate CF lung disease; - explore evidence of activity of INS37217 and placebo administered via PARI LC STAR nebulizer; - identify dose(s) that will be studied in subsequent trials.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 8 Years/50 Years
Genders: Both
Protocol Entry Criteria: - confirmed diagnosis of CF - FEV1 greater than or equal to 75% of predicted normal - oxyhemoglobin saturation greater than or equal to 90% - clinically stable
Total Enrollment: 92
Location and Contact Information:
University of Washington Medical Center
Seattle, Washington, 98195
United States
The Children's Hospital
Denver, Colorado, 80218
United States
Texas Children's Hospital
Houston, Texas, 77030
United States
Cincinnati's Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039
United States
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27514
United States
Stanford University Hospital and Clinics
Palo Alto, California, 94305
United States
Children's Hospital
Boston, Massachusetts, 02115
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
Cardinal Glennon Children's Hospital
St. Louis, Missouri, 63104
United States
The Johns Hopkins Hospital
Baltimore, Maryland, 21287
United States
Children's Memorial Hospital
Chicago, Illinois, 60614
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
University of Minnesota General Clinical Research Center
Minneapolis, Minnesota, 55455
United States
Columbus Children's Hospital
Columbus, Ohio, 43205
United States
Fairview University Medical Center
Minneapolis, Minnesota, 55455
United States
Children's Hospital and Regional Medical Center
Seattle, Washington, 98105
United States
Additional Information:
Study ID Numbers: 08-103;
Study Start Date: March 2003
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056147
Other Cystic Fibrosis Studies:
1. Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis
2. Bone Health of People with Cystic Fibrosis
3. Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
4. Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
5. A multi-centered study of the long-term effect of salmeterol and albuterol in cystic fibrosis
Related Studies:
Other Cystic Fibrosis Clinical Trials
Other North Carolina Clinical Trials
Other Chapel Hill Clinical Trials
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
|
|
|
|
|
|
|
|
